Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio (NASDAQ: INMB) announced plans to release a video detailing additional findings from their Phase 2 MINDFuL trial of XPro™, their selective soluble TNF inhibitor for Alzheimer's disease. The video will follow their presentation at the Alzheimer's Association International Conference (AAIC) in Toronto.
The trial demonstrated that XPro™ showed consistent benefits after 6 months in patients with amyloid-beta pathology and specific inflammatory biomarkers. Dr. Sharon Cohen will present the data at AAIC on July 29, 2025, from 2:00 to 3:30 PM ET, with the detailed video becoming available on July 31, 2025, at 4 PM ET on INmune Bio's YouTube channel.
INmune Bio (NASDAQ: INMB) will present additional analyses from its Phase 2 MINDFuL trial of XPro™, a selective soluble TNF inhibitor for Alzheimer's disease, at the AAIC in Toronto on July 29, 2025.
The trial enrolled 208 participants with early-stage Alzheimer's, randomized 2:1 to receive XPro™ or placebo. While the primary endpoint wasn't met in the overall mITT group, the treatment showed consistent benefits after 6 months in a subgroup with confirmed amyloid-beta pathology and multiple inflammation biomarkers.
Dr. Sharon Cohen will present the findings, and INmune Bio plans to publish results by mid-August while seeking strategic partnerships for XPro™'s further development.
INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has successfully closed its previously announced registered direct offering. The company sold 3,000,000 shares of common stock at $6.30 per share, raising approximately $19 million in gross proceeds before deducting fees and expenses.
The offering was priced at-the-market under Nasdaq rules and was conducted through A.G.P./Alliance Global Partners as the sole placement agent. The company plans to utilize the net proceeds for working capital purposes and general corporate procedures. The offering was executed under an effective shelf registration statement on Form S-3.
INmune Bio (NASDAQ: INMB) has reported results from its Phase 2 MINDFuL trial evaluating XPro™, a selective soluble TNF inhibitor, in early Alzheimer's Disease (AD). While the modified intent-to-treat population (n=200) did not meet the primary cognitive endpoint, a predefined subgroup of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100) showed positive results.
Key findings in the subgroup demonstrated:
- Clinical benefit on the primary endpoint EMACC (effect size: 0.27)
- Improvement on the Neuropsychiatric Inventory (effect size: -0.24)
- Biological benefit in blood levels of pTau217 (effect size: -0.20)
The treatment was well-tolerated with no occurrences of ARIA-E or ARIA-H, even in high-risk ApoE4+/+ patients. The most common adverse events were injection site reactions, affecting 80% of the XPro™ group. The company plans to file for Breakthrough Therapy Designation with the FDA and schedule an End-of-Phase 2 meeting in Q4 2025 to define the path for a pivotal trial.
INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has announced a registered direct offering of 3,000,000 shares of common stock priced at $6.30 per share. The offering, expected to close around June 30, 2025, aims to raise approximately $19 million in gross proceeds.
The offering is priced at-the-market under Nasdaq rules, with A.G.P./Alliance Global Partners serving as the sole placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The offering is being made through an effective shelf registration statement previously filed with the SEC.
INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has scheduled a conference call to present top line data from their Phase 2 MINDFuL trial in early Alzheimer's Disease. The call will take place on June 30, 2025, at 8:00 AM EDT.
Investors can access the presentation through a dial-in number (+1-800-267-6316 for US, +1-203-518-9783 for international) or via webcast. A transcript will be available within 24 hours, and a replay will be accessible through July 30, 2025.
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company focused on inflammation and immunology through innate immune system targeting, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The event will take place on May 20-21, 2025, at the InterContinental Barclay NY. The company will participate in a fireside chat and conduct one-on-one virtual meetings, with their presentation scheduled for 11:00 AM EDT.
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company focused on treating Alzheimer's Disease through targeting microglial activation and neuroinflammation, has scheduled its Q1 2025 earnings conference call for May 8th, 2025, at 4:30 PM EDT. The call will cover financial results for the quarter ended March 31, 2025, and provide a corporate update.
Participants can join via phone using the domestic dial-in (1-800-267-6316) or international dial-in (+1-203-518-9783) with Conference ID: INMUNE. A live audio webcast will be available, and a transcript will be provided approximately 24 hours after the call. A replay will be accessible through May 22nd, 2025.
INmune Bio (NASDAQ: INMB) has achieved a significant intellectual property milestone for its CORDStrom™ platform technology. The USPTO has issued a favorable written opinion on all claims in the company's international patent application PCT/US25/17028, confirming novelty, inventive step, and industrial applicability for their next-generation mesenchymal stromal cell (MSC) product.
CORDStrom™, comprising pooled, culture-expanded human umbilical cord-derived MSCs, is designed for infusion or injection across various inflammatory and degenerative diseases. The patent, once granted, will provide IP exclusivity through at least 2045. The company plans to expedite the U.S. application via the Patent Prosecution Highway program.
Recent Phase 2 trial data showed promising results, with CORDStrom™ demonstrating reductions in pain and itch, along with early signals of improved skin integrity and disease activity.